{"id":355445,"date":"2026-11-19T15:02:34","date_gmt":"2026-11-19T09:32:34","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=355445"},"modified":"2026-11-19T15:02:34","modified_gmt":"2026-11-19T09:32:34","slug":"nephrocare-health-services-share-price-target-2027","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/","title":{"rendered":"Nephrocare Health Services Share Price Target 2027: 19.9% Upside to Rs 783, Bull Rs 938"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Nephrocare Health Services share price Rs 653.00 (19 November 2026). Base target Rs 783, bull Rs 938, downside risk Rs 522. PE 51.35. 52W range Rs 446.00 to Rs 781.50.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The <strong>Nephrocare Health Services share price target<\/strong> for 2027 is <strong>Rs 783<\/strong>, about <strong>19.9%<\/strong> above the current price of Rs 653.00. The <strong>bull case<\/strong> is <strong>Rs 938<\/strong>, and the <strong>downside risk level<\/strong>, which is not a target, is <strong>Rs 522<\/strong>. The base case assumes earnings per share grow 20.0% a year, a cap applied because the FY24 to FY26 pace was 35.7%, with the stock holding its PE of 51.35. These are model-based estimates built from reported financials, not guaranteed outcomes.<\/p>\n<\/p><\/div>\n<p>Investors weighing a <strong>Nephrocare Health Services target price<\/strong> for 2027 should start with where the stock sits today. At Rs 653.00 on 19 November 2026, it is 16.4% below its 52-week high of Rs 781.50 and 46.4% above its 52-week low of Rs 446.00. That range spans 75% from low to high, so the entry point matters as much as the <strong>Nephrocare Health Services price forecast<\/strong> itself.<\/p>\n<p>This article builds the <strong>Nephrocare Health Services share price target<\/strong> from reported numbers only: three years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the <strong>bull case<\/strong> and the <strong>downside risk level<\/strong> were reached and test them against your own view.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=nephrocare-health-services-share-price-target-2027\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Nephrocare_Health_Services_Stock_Analysis_Company_Overview_and_Key_Stats\" title=\"Nephrocare Health Services Stock Analysis: Company Overview and Key Stats\">Nephrocare Health Services Stock Analysis: Company Overview and Key Stats<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Why_Is_Nephrocare_Health_Services_Share_Price_Target_Set_at_Rs_783_for_2027\" title=\"Why Is Nephrocare Health Services Share Price Target Set at Rs 783 for 2027?\">Why Is Nephrocare Health Services Share Price Target Set at Rs 783 for 2027?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Earnings_Growth_Behind_the_Nephrocare_Health_Services_Target_Price_Three_Years_of_Results\" title=\"Earnings Growth Behind the Nephrocare Health Services Target Price: Three Years of Results\">Earnings Growth Behind the Nephrocare Health Services Target Price: Three Years of Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Margins_and_the_Latest_Quarter\" title=\"Margins and the Latest Quarter\">Margins and the Latest Quarter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Balance_Sheet_and_Cash_Flow\" title=\"Balance Sheet and Cash Flow\">Balance Sheet and Cash Flow<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Valuation_Check_for_the_Nephrocare_Health_Services_Stock_Target_PE_Price_to_Book_and_ROE\" title=\"Valuation Check for the Nephrocare Health Services Stock Target: PE, Price to Book and ROE\">Valuation Check for the Nephrocare Health Services Stock Target: PE, Price to Book and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Shareholding_Pattern_and_Institutional_Holding\" title=\"Shareholding Pattern and Institutional Holding\">Shareholding Pattern and Institutional Holding<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Nephrocare_Health_Services_Share_Price_Targets_for_the_Short_Term_and_12_Months\" title=\"Nephrocare Health Services Share Price Targets for the Short Term and 12 Months\">Nephrocare Health Services Share Price Targets for the Short Term and 12 Months<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Short_Term_Nephrocare_Health_Services_Stock_Target_Levels_Technical_Setup\" title=\"Short Term Nephrocare Health Services Stock Target Levels: Technical Setup\">Short Term Nephrocare Health Services Stock Target Levels: Technical Setup<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#12_Month_Nephrocare_Health_Services_Target_Price_for_2027\" title=\"12 Month Nephrocare Health Services Target Price for 2027\">12 Month Nephrocare Health Services Target Price for 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#How_EPS_Growth_and_PE_Multiple_Change_the_Nephrocare_Health_Services_Target_Price\" title=\"How EPS Growth and PE Multiple Change the Nephrocare Health Services Target Price\">How EPS Growth and PE Multiple Change the Nephrocare Health Services Target Price<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Bull_Case_and_Downside_Risk_for_Nephrocare_Health_Services_Stock_Target_in_2027\" title=\"Bull Case and Downside Risk for Nephrocare Health Services Stock Target in 2027\">Bull Case and Downside Risk for Nephrocare Health Services Stock Target in 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Bull_Case_Rs_938\" title=\"Bull Case Rs 938\">Bull Case Rs 938<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Downside_Risk_Level_Rs_522\" title=\"Downside Risk Level Rs 522\">Downside Risk Level Rs 522<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Key_Risks_to_the_Nephrocare_Health_Services_Target_Price_for_2027\" title=\"Key Risks to the Nephrocare Health Services Target Price for 2027\">Key Risks to the Nephrocare Health Services Target Price for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Growth_Slowdown_Risk_for_the_Nephrocare_Health_Services_Price_Target\" title=\"Growth Slowdown Risk for the Nephrocare Health Services Price Target\">Growth Slowdown Risk for the Nephrocare Health Services Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Liquidity_and_Size_Risk\" title=\"Liquidity and Size Risk\">Liquidity and Size Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Valuation_and_Margin_Risk\" title=\"Valuation and Margin Risk\">Valuation and Margin Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Market_and_Technical_Risk\" title=\"Market and Technical Risk\">Market and Technical Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#How_to_Invest_in_Nephrocare_Health_Services\" title=\"How to Invest in Nephrocare Health Services\">How to Invest in Nephrocare Health Services<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#FAQs_on_Nephrocare_Health_Services_Share_Price_Target_2027\" title=\"FAQs on Nephrocare Health Services Share Price Target 2027\">FAQs on Nephrocare Health Services Share Price Target 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#What_is_the_Nephrocare_Health_Services_share_price_target_for_2027\" title=\"What is the Nephrocare Health Services share price target for 2027?\">What is the Nephrocare Health Services share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#What_is_the_Nephrocare_Health_Services_share_price_today\" title=\"What is the Nephrocare Health Services share price today?\">What is the Nephrocare Health Services share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Is_Nephrocare_Health_Services_a_buy_or_sell_at_the_current_price\" title=\"Is Nephrocare Health Services a buy or sell at the current price?\">Is Nephrocare Health Services a buy or sell at the current price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#What_are_the_bull_case_target_and_downside_risk_level_for_Nephrocare_Health_Services_shares\" title=\"What are the bull case target and downside risk level for Nephrocare Health Services shares?\">What are the bull case target and downside risk level for Nephrocare Health Services shares?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#What_are_the_main_risks_to_the_Nephrocare_Health_Services_price_target\" title=\"What are the main risks to the Nephrocare Health Services price target?\">What are the main risks to the Nephrocare Health Services price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#What_is_the_PE_ratio_of_Nephrocare_Health_Services_and_how_does_it_compare_with_the_industry\" title=\"What is the PE ratio of Nephrocare Health Services and how does it compare with the industry?\">What is the PE ratio of Nephrocare Health Services and how does it compare with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#Who_owns_Nephrocare_Health_Services_and_what_is_the_promoter_holding\" title=\"Who owns Nephrocare Health Services, and what is the promoter holding?\">Who owns Nephrocare Health Services, and what is the promoter holding?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/nephrocare-health-services-share-price-target-2027\/#What_were_Nephrocare_Health_Services_latest_quarterly_results\" title=\"What were Nephrocare Health Services&#8217; latest quarterly results?\">What were Nephrocare Health Services&#8217; latest quarterly results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Nephrocare_Health_Services_Stock_Analysis_Company_Overview_and_Key_Stats\"><\/span><strong>Nephrocare Health Services Stock Analysis: Company Overview and Key Stats<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Nephrocare Health Services (NSE: NEPHROPLUS) has a market capitalisation of Rs 6,581 crore. In FY26 it reported revenue of Rs 1,023 crore and net profit of Rs 76.84 crore. The table collects the figures the <strong>Nephrocare Health Services share price target<\/strong> is built on.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>Company<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/nephroplus\/nephrocare-health-serv-l-share-price-today\">Nephrocare Health Services<\/a><\/td>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>NEPHROPLUS<\/td>\n<\/tr>\n<tr>\n<td>CMP (19 November 2026)<\/td>\n<td>Rs 653.00<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 781.50<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 446.00<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 6,581 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>51.35<\/td>\n<\/tr>\n<tr>\n<td>Industry PE<\/td>\n<td>63.96<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>5.53<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>10.78%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.13<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 12.70<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.00%<\/td>\n<\/tr>\n<tr>\n<td>12-Month Base Target<\/td>\n<td>Rs 783<\/td>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 938<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk Level (not a target)<\/td>\n<td>Rs 522<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_Nephrocare_Health_Services_Share_Price_Target_Set_at_Rs_783_for_2027\"><\/span><strong>Why Is Nephrocare Health Services Share Price Target Set at Rs 783 for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The arithmetic is short. Trailing EPS of Rs 12.70 grown for one year gives a forward <strong>EPS estimate<\/strong> of Rs 15.24, and multiplying it by the unchanged PE of 51.35 gives the <strong>Rs 783<\/strong> base-case <strong>Nephrocare Health Services stock target<\/strong>. The <strong>bull case<\/strong> adds faster earnings growth and a higher multiple, while the <strong>downside risk level<\/strong> assumes flat earnings and a lower multiple.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Earnings_Growth_Behind_the_Nephrocare_Health_Services_Target_Price_Three_Years_of_Results\"><\/span><strong>Earnings Growth Behind the Nephrocare Health Services Target Price: Three Years of Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Nephrocare Health Services grew revenue from Rs 574.72 crore in FY24 to Rs 1,023 crore in FY26, a compound annual growth rate of 33.4%. Net profit grew faster, from Rs 35.13 crore to Rs 76.84 crore (47.9% a year), which shows margin gains did part of the work and not just higher sales.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Financial Year<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<th>EPS (Rs)<\/th>\n<th>Dividend per Share (Rs)<\/th>\n<\/tr>\n<tr>\n<td>FY24<\/td>\n<td>574.72<\/td>\n<td>35.13<\/td>\n<td>4.40<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>FY25<\/td>\n<td>769.91<\/td>\n<td>67.10<\/td>\n<td>8.01<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>FY26<\/td>\n<td>1,023.36<\/td>\n<td>76.84<\/td>\n<td>8.10<\/td>\n<td>0.00<\/td>\n<\/tr>\n<\/table>\n<p>FY26 revenue growth was 32.9%, close to the two-year average of 33.4%, and net profit moved up 14.5%. EPS rose from Rs 4.40 in FY24 to Rs 8.10 in FY26. The <strong>FY27 outlook<\/strong> for the <strong>Nephrocare Health Services price target<\/strong> depends on whether that <strong>EPS estimate<\/strong> keeps compounding.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margins_and_the_Latest_Quarter\"><\/span><strong>Margins and the Latest Quarter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Nephrocare Health Services converted 7.5% of FY26 revenue into net profit, against 8.7% in FY25, within a three-year range of 6.1% to 8.7%. EBITDA margin was 24.3% in FY26 versus 23.5% in FY25.<\/p>\n<p>In the September 2026 quarter, revenue was Rs 311.40 crore, up 24.8% from the same quarter a year earlier, and the company reported a net profit of Rs 33.53 crore, against a loss of Rs 9.47 crore in the same quarter a year earlier. EBITDA came in at Rs 75.11 crore, up 10.8% year on year. The next quarterly result is the first test of whether the earnings assumption behind the <strong>Nephrocare Health Services stock target<\/strong> holds.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Balance_Sheet_and_Cash_Flow\"><\/span><strong>Balance Sheet and Cash Flow<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Debt to equity stands at 0.13, and shareholders&#8217; equity grew from Rs 413.71 crore in FY24 to Rs 1,116 crore in FY26. Operating cash flow in FY26 was Rs 232.58 crore against capital expenditure of Rs 119.36 crore, leaving free cash flow of Rs 113.22 crore, or 1.7% of the current market capitalisation. In FY25 free cash flow was Rs 34.55 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Check_for_the_Nephrocare_Health_Services_Stock_Target_PE_Price_to_Book_and_ROE\"><\/span><strong>Valuation Check for the Nephrocare Health Services Stock Target: PE, Price to Book and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At a PE of 51.35 against an industry PE of 63.96, Nephrocare Health Services trades at a discount to its industry. Price to book is 5.53 on a book value of Rs 117.84 per share, and return on equity is 10.78%. A PE of 51.35 equals an earnings yield of 1.9%, and the FY26 dividend of Rs 0.00 per share gives a yield of 0.00%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Shareholding_Pattern_and_Institutional_Holding\"><\/span><strong>Shareholding Pattern and Institutional Holding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Promoters held 58.31% of Nephrocare Health Services in September 2026, and promoter holding fell from 63.85% in December 2025 to 58.31% in September 2026. Foreign institutional investors (FII) held 11.73% and domestic institutions (DII) held 8.11%, which puts total <strong>institutional holding<\/strong> at 19.84%. FII holding rose from 9.30% in December 2025 to 11.73% in September 2026. Public shareholders own the remaining 21.85%. A meaningful institutional holding adds a layer of research coverage and trading depth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Nephrocare_Health_Services_Share_Price_Targets_for_the_Short_Term_and_12_Months\"><\/span><strong>Nephrocare Health Services Share Price Targets for the Short Term and 12 Months<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Nephrocare_Health_Services_Stock_Target_Levels_Technical_Setup\"><\/span><strong>Short Term Nephrocare Health Services Stock Target Levels: Technical Setup<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 653.00 on 19 November 2026, Nephrocare Health Services trades below its 50-day simple moving average of Rs 658.02 and above its 200-day exponential moving average of Rs 622.63. The 14-day RSI reads 57.6, which is neutral territory, and the MACD line sits above its signal line. The nearest <strong>resistance level<\/strong> is Rs 658.02 (50-day simple moving average) and the nearest support is Rs 622.63 (200-day exponential moving average). A sustained move above Rs 658.02 would improve the short-term setup, while a close below Rs 622.63 would shift attention to the next support.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12_Month_Nephrocare_Health_Services_Target_Price_for_2027\"><\/span><strong>12 Month Nephrocare Health Services Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>12-month target<\/strong> of <strong>Rs 783<\/strong> means a move of 19.9% up from Rs 653.00 over the next 12 months. It would also push the stock above its 52-week high of Rs 781.50. Anyone checking the <strong>Nephrocare Health Services share price target<\/strong> against their own view should focus on two inputs: the EPS estimate and the <strong>PE multiple<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_EPS_Growth_and_PE_Multiple_Change_the_Nephrocare_Health_Services_Target_Price\"><\/span><strong>How EPS Growth and PE Multiple Change the Nephrocare Health Services Target Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>EPS Growth<\/th>\n<th>PE 41.08<\/th>\n<th>PE 51.35<\/th>\n<th>PE 59.05<\/th>\n<\/tr>\n<tr>\n<td>0.0% (EPS Rs 12.70)<\/td>\n<td>Rs 522<\/td>\n<td>Rs 652<\/td>\n<td>Rs 750<\/td>\n<\/tr>\n<tr>\n<td>20.0% (EPS Rs 15.24)<\/td>\n<td>Rs 626<\/td>\n<td>Rs 783<\/td>\n<td>Rs 900<\/td>\n<\/tr>\n<tr>\n<td>25.0% (EPS Rs 15.88)<\/td>\n<td>Rs 652<\/td>\n<td>Rs 815<\/td>\n<td>Rs 938<\/td>\n<\/tr>\n<\/table>\n<p>Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the <strong>Nephrocare Health Services price forecast<\/strong>, and reading down a column shows what earnings growth is worth at a fixed multiple.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Downside_Risk_for_Nephrocare_Health_Services_Stock_Target_in_2027\"><\/span><strong>Bull Case and Downside Risk for Nephrocare Health Services Stock Target in 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_938\"><\/span><strong>Bull Case Rs 938<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bull case<\/strong> <strong>Nephrocare Health Services price target<\/strong> needs EPS growth of 25.0%, which lifts forward EPS to Rs 15.88, and a <strong>PE multiple<\/strong> that rises 15% to 59.05. That gives <strong>Rs 938<\/strong>, 43.6% above the current price and above the 52-week high of Rs 781.50, so the stock would have to set a fresh 52-week high.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Downside_Risk_Level_Rs_522\"><\/span><strong>Downside Risk Level Rs 522<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The downside risk level is not a target. It assumes EPS stays flat at Rs 12.70 and the PE falls 20% to 41.08. That gives <strong>Rs 522<\/strong>, 20.1% below the current price and above the 52-week low of Rs 446.00.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Scenario<\/th>\n<th>EPS Growth<\/th>\n<th>PE Multiple<\/th>\n<th>Price (Rs)<\/th>\n<th>Change vs CMP<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>25.0%<\/td>\n<td>59.05<\/td>\n<td>Rs 938<\/td>\n<td>+43.6%<\/td>\n<\/tr>\n<tr>\n<td>Base Case<\/td>\n<td>20.0%<\/td>\n<td>51.35<\/td>\n<td>Rs 783<\/td>\n<td>+19.9%<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk<\/td>\n<td>0.0%<\/td>\n<td>41.08<\/td>\n<td>Rs 522<\/td>\n<td>-20.1%<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Nephrocare_Health_Services_Target_Price_for_2027\"><\/span><strong>Key Risks to the Nephrocare Health Services Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Growth_Slowdown_Risk_for_the_Nephrocare_Health_Services_Price_Target\"><\/span><strong>Growth Slowdown Risk for the Nephrocare Health Services Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue in the September 2026 quarter was up 24.8% year on year, and FY26 revenue growth was 32.9%. If growth slows from here, the EPS estimate behind the Nephrocare Health Services stock target will need revising.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_and_Size_Risk\"><\/span><strong>Liquidity and Size Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Nephrocare Health Services has a market capitalisation of Rs 6,581 crore. <strong>Institutional holding<\/strong> is 19.84%, and promoters hold 58.31%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Margin_Risk\"><\/span><strong>Valuation and Margin Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net margin was 7.5% in FY26, so a small slip in costs moves profit noticeably. At a PE of 51.35 versus an industry PE of 63.96, a de-rating toward the downside-risk PE of 41.08 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Market_and_Technical_Risk\"><\/span><strong>Market and Technical Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Technical indicators add short-term risk: the 14-day RSI is 57.6 and the MACD sits above its signal line. A broad fall in the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> or the <a href=\"https:\/\/univest.in\/indices\/sensex\/sensex-share-price-today\">Sensex<\/a> can override company fundamentals for weeks at a time.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Nephrocare_Health_Services\"><\/span><strong>How to Invest in Nephrocare Health Services<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start with the live price and volume. Any <strong>Nephrocare Health Services share price target<\/strong> is only as current as the data behind it, and the data here is as of 19 November 2026, so refresh the Rs 653.00 price before acting on any level.<\/p>\n<p>Next, review the fundamentals yourself. The Univest Screener lets you check Nephrocare Health Services&#8217; PE, ROE, debt and shareholding in one place.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Nephrocare Health Services fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<p>Then compare the three <strong>Nephrocare Health Services target price<\/strong> scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.<\/p>\n<p>Decide your position size and exit levels before you buy. The support and <strong>resistance level<\/strong>s above can serve as reference points, but they are not recommendations.<\/p>\n<p>Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Nephrocare Health Services live price and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Nephrocare Health Services share price target<\/strong> for 2027 is Rs 783 in the base case, with <strong>Rs 938<\/strong> as the bull case. The support for that view is arithmetic you can check: EPS grew 35.7% a year over FY24 to FY26, and the stock trades at a PE of 51.35. The risks are equally concrete, including a net margin of just 7.5% that leaves profit sensitive to costs and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework for judging the <strong>Nephrocare Health Services price target<\/strong>, check them against the latest filings, and size any position to your own risk appetite.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Nephrocare_Health_Services_Share_Price_Target_2027\"><\/span><strong>FAQs on Nephrocare Health Services Share Price Target 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Nephrocare_Health_Services_share_price_target_for_2027\"><\/span><strong>What is the Nephrocare Health Services share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The base-case Nephrocare Health Services share price target for 2027 is Rs 783, which is 19.9% above the price of Rs 653.00 on 19 November 2026. The bull case is Rs 938 and the downside risk level, which is not a target, is Rs 522. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Nephrocare_Health_Services_share_price_today\"><\/span><strong>What is the Nephrocare Health Services share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 19 November 2026, before market open, Nephrocare Health Services (NSE: NEPHROPLUS) is quoted at Rs 653.00, which is its last closing price from the previous session. That is 16.4% below the 52-week high of Rs 781.50 and 46.4% above the 52-week low of Rs 446.00. The market capitalisation of Rs 6,581 crore places it among mid-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Nephrocare_Health_Services_a_buy_or_sell_at_the_current_price\"><\/span><strong>Is Nephrocare Health Services a buy or sell at the current price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The data points both ways. On the positive side, EPS has grown 35.7% a year over FY24 to FY26 and the base case implies 19.9% upside; on the cautious side, the net margin is a thin 7.5%, and the downside risk level of Rs 522 is 20% below the current price. Whether Nephrocare Health Services fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_bull_case_target_and_downside_risk_level_for_Nephrocare_Health_Services_shares\"><\/span><strong>What are the bull case target and downside risk level for Nephrocare Health Services shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case in the Nephrocare Health Services share price target for 2027 is Rs 938, which assumes 25.0% EPS growth and a PE of 59.05, a 15% re-rating from today&#8217;s multiple. That is 43.6% above the current price and above the 52-week high of Rs 781.50, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 522, which assumes flat EPS and a PE of 41.08, 20% lower than today. It sits 20.1% below the current price and above the 52-week low of Rs 446.00, and it marks a risk to watch, not a target.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_to_the_Nephrocare_Health_Services_price_target\"><\/span><strong>What are the main risks to the Nephrocare Health Services price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Four risks matter most for the Nephrocare Health Services share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 6,581 crore, the stock is usually liquid, though exits can take longer than entries in a falling market. A fall to the downside-risk PE of 41.08 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PE_ratio_of_Nephrocare_Health_Services_and_how_does_it_compare_with_the_industry\"><\/span><strong>What is the PE ratio of Nephrocare Health Services and how does it compare with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The PE ratio of Nephrocare Health Services is 51.35, against an industry PE of 63.96, which is a discount to the industry. Price to book is 5.53 and return on equity is 10.78%, and the PE equals an earnings yield of 1.9%. The base case holds the PE unchanged, so the Nephrocare Health Services share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Who_owns_Nephrocare_Health_Services_and_what_is_the_promoter_holding\"><\/span><strong>Who owns Nephrocare Health Services, and what is the promoter holding?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Promoters held 58.31% of Nephrocare Health Services in September 2026. FII held 11.73%, DII held 8.11% and the public held 21.85%. Together the two institutional groups hold 19.84%. Shareholding is filed every quarter, so it is worth rechecking after each result.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Nephrocare_Health_Services_latest_quarterly_results\"><\/span><strong>What were Nephrocare Health Services&#8217; latest quarterly results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> In the September 2026 quarter, Nephrocare Health Services reported revenue of Rs 311.40 crore (up 24.8% year on year) and net profit of Rs 33.53 crore (against a loss of Rs 9.47 crore in the same quarter a year earlier). For comparison, FY26 full-year revenue growth was 32.9% and net profit moved up 14.5%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Nephrocare Health Services share price target for 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The base-case Nephrocare Health Services share price target for 2027 is Rs 783, which is 19.9% above the price of Rs 653.00 on 19 November 2026. The bull case is Rs 938 and the downside risk level, which is not a target, is Rs 522. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.\"}},{\"@type\":\"Question\",\"name\":\"What is the Nephrocare Health Services share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 19 November 2026, before market open, Nephrocare Health Services (NSE: NEPHROPLUS) is quoted at Rs 653.00, which is its last closing price from the previous session. That is 16.4% below the 52-week high of Rs 781.50 and 46.4% above the 52-week low of Rs 446.00. The market capitalisation of Rs 6,581 crore places it among mid-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.\"}},{\"@type\":\"Question\",\"name\":\"Is Nephrocare Health Services a buy or sell at the current price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The data points both ways. On the positive side, EPS has grown 35.7% a year over FY24 to FY26 and the base case implies 19.9% upside; on the cautious side, the net margin is a thin 7.5%, and the downside risk level of Rs 522 is 20% below the current price. Whether Nephrocare Health Services fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.\"}},{\"@type\":\"Question\",\"name\":\"What are the bull case target and downside risk level for Nephrocare Health Services shares?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The bull case in the Nephrocare Health Services share price target for 2027 is Rs 938, which assumes 25.0% EPS growth and a PE of 59.05, a 15% re-rating from today's multiple. That is 43.6% above the current price and above the 52-week high of Rs 781.50, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 522, which assumes flat EPS and a PE of 41.08, 20% lower than today. It sits 20.1% below the current price and above the 52-week low of Rs 446.00, and it marks a risk to watch, not a target.\"}},{\"@type\":\"Question\",\"name\":\"What are the main risks to the Nephrocare Health Services price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Four risks matter most for the Nephrocare Health Services share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 6,581 crore, the stock is usually liquid, though exits can take longer than entries in a falling market. A fall to the downside-risk PE of 41.08 would cut the price even if earnings hold.\"}},{\"@type\":\"Question\",\"name\":\"What is the PE ratio of Nephrocare Health Services and how does it compare with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The PE ratio of Nephrocare Health Services is 51.35, against an industry PE of 63.96, which is a discount to the industry. Price to book is 5.53 and return on equity is 10.78%, and the PE equals an earnings yield of 1.9%. The base case holds the PE unchanged, so the Nephrocare Health Services share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.\"}},{\"@type\":\"Question\",\"name\":\"Who owns Nephrocare Health Services, and what is the promoter holding?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Promoters held 58.31% of Nephrocare Health Services in September 2026. FII held 11.73%, DII held 8.11% and the public held 21.85%. Together the two institutional groups hold 19.84%. Shareholding is filed every quarter, so it is worth rechecking after each result.\"}},{\"@type\":\"Question\",\"name\":\"What were Nephrocare Health Services' latest quarterly results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"In the September 2026 quarter, Nephrocare Health Services reported revenue of Rs 311.40 crore (up 24.8% year on year) and net profit of Rs 33.53 crore (against a loss of Rs 9.47 crore in the same quarter a year earlier). For comparison, FY26 full-year revenue growth was 32.9% and net profit moved up 14.5%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nephrocare Health Services share price target 2027: base Rs 783, bull Rs 938, downside risk level Rs 522, built from reported earnings, valuation and shareholding data.<\/p>\n","protected":false},"author":38,"featured_media":355444,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[1019],"class_list":["post-355445","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["355444"],"rank_math_title":["Nephrocare Health Services Share Price Target 2027: 19.9% Upside"],"rank_math_description":["The Nephrocare Health Services share price target for 2027 is Rs 783 against a price of Rs 653.00. Bull case, downside risk, earnings and risks explained. November 2026."],"rank_math_focus_keyword":["Nephrocare Health Services share price target | Density Target: 1.2 to 1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/nephrocare-health-services-share-price-target-2027-19-9-upside-to-rs-783-bull-rs.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=355445"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355445\/revisions"}],"predecessor-version":[{"id":355446,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355445\/revisions\/355446"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/355444"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=355445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=355445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=355445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}